Related Experiment Videos
Side-firing Neodymium:YAG laser prostatectomy
1Department of Urology, St. Vincent's Hospital, Melbourne, Vic., Australia.
European Urology
|February 6, 1999
Summary
Laser therapy for benign prostatic hyperplasia (BPH) is now a viable option, with Neodymium:YAG laser prostatectomy showing comparable efficacy and safety to traditional TURP. Future advancements like Holmium:YAG may offer further improvements.
Area of Science:
- Urology
- Medical Technology
- Laser Surgery
Background:
- Benign prostatic hyperplasia (BPH) treatment historically relied on methods with limited applicability.
- The advent of side-firing free beam laser delivery devices revolutionized BPH treatment options.
Purpose of the Study:
- To evaluate the evolution and efficacy of laser therapy in treating benign prostatic hyperplasia.
- To compare Neodymium:YAG laser prostatectomy with conventional transurethral resection of the prostate (TURP).
Main Methods:
- Review of studies on Neodymium:YAG (Neodymium:YAG) laser coagulative prostatectomy.
- Comparison of laser therapy outcomes with electrocautery TURP over the past five years.
Main Results:
- Neodymium:YAG laser therapy has become a feasible option for urologists since 1991.
- Studies demonstrate Neodymium:YAG laser prostatectomy is equivalent in efficacy and safety to conventional TURP.
- Holmium:YAG laser technology presents a potential advancement over current free beam laser methods.
Conclusions:
- Laser therapy, particularly Neodymium:YAG coagulative prostatectomy, is a safe and effective treatment for BPH.
- Technological refinements have expanded the utility of laser prostatectomy.
- Emerging technologies like Holmium:YAG promise further advancements in BPH management.